PFLPhysiological Fitness Landscape

Biomarkers · Cardiac & Hemodynamics

Carotid-Femoral Pulse Wave Velocity (PWV)

Lower values carry lower risk. Not measured in our NHANES panel; the curve is synthesised from the published association.

Hazard ratio relative to the curve's reference value, as synthesised from the published association.

Published hazard ratio1.35per SD (95% CI 1.24–1.47) · Arterial Stiffness Meta-Analysis (17 Prospective Studies)

Where people sit

Population percentiles (m/s) by sex and age band. Cycle or source as recorded in the catalogue.

SexAge5th25thMedian75th95thnCycle / source
All20-394.805.606.307.208.801,580Calibrated Reference
All40-595.606.807.809.2011.51,560Calibrated Reference
All60+7.208.8010.412.416.21,660Calibrated Reference
Allall5.406.808.009.6013.24,800Calibrated Reference
Menall5.507.008.209.9013.62,350Calibrated Reference
Womenall5.306.607.809.3012.82,450Calibrated Reference

What studies found when this marker was changed

Effects on the biomarker reported in the cited studies. They describe what happened in those populations, not a recommendation for anyone. See all catalogued interventions.

TypeInterventionReported effectEvidenceSource
behavioralChronic heavy cigarette smoking+1.0 to +2.5 m/s elevation via elastin degradationmeta-analysisVlachopoulos C, et al. J Am Coll Cardiol. 2010;55:1318-1327.
clinicalAdvanced vascular calcification in chronic kidney disease / diabetes+2.5 to +6.0 m/s elevation (>10.0 m/s, high CV event risk)prospective cohortBlacher J, et al. Circulation. 1999;99:2434-2439.
dietDietary sodium restriction and dietary nitrate / polyphenol supplementation-0.5 to -1.0 m/s reductionrctJuraschek SP, et al. J Am Coll Cardiol. 2017;70:2748-2757.
exerciseLifelong aerobic endurance exercise and blood pressure controlLowers cfPWV by 1.0-2.0 m/s (equivalent to 10-15 years younger vascular age)meta-analysisRapsomaniki E, et al. Blood pressure and risk of vascular disease: 1.25 million …
exerciseLong-term aerobic endurance and cycling / running exercise-0.8 to -1.8 m/s reduction in arterial stiffnessmeta-analysisAshor AW, et al. Sports Med. 2014;44:1773-1788.
pharmacologicRAAS inhibitor therapy (ACE inhibitors / ARBs)-0.7 to -1.5 m/s reduction via vascular remodelingmeta-analysisOng KT, et al. J Hypertens. 2011;29:1439-1449.